Platelets, which contain many growth factors such as platelet-derived growth factor (PDGF) and transforming growth factor-β (TGF-β), are being used in clinical applications as platelet-rich plasma (PRP). Only a few studies, however, have been conducted on the growth factors present in PRP and on the clinical applications using the drug delivery system (DDS). For the purpose of clinical application, we first modified the PRP preparation method and assessed the amounts of growth factors contained in the human platelet concentrates. Furthermore, we assessed fibrin glue as a DDS of platelet concentrates. Platelet precipitations were made by twice centrifuging human whole blood. The precipitated platelet was resuspended to yield the platelet concentrates. The growth factor concentrations were measured. Fibrin glue sheets containing this platelet concentrate were implanted in rabbit pinna and samples were obtained for immunostaining (anti-PDGF antibody) to assess the use of PRP over time using the fibrin glue as the DDS. The mean concentration of growth factors present in the platelet concentrates was three times or greater than that of conventional PRP. Furthermore, the results indicated that when the platelet concentrate was used with fibrin glue as a carrier, the contents were released over a period of about 1 week. This raises the possibility that this system may be useful in clinical applications.
INTRODUCTION
clinical applications of platelet-rich plasma (PRP) to promote periodontal tissue regeneration in periodontal defects and bone formation in maxillary defects and im-In addition to procoagulant effects, platelets are known to contain various growth factors involved in the repair plant treatments (1, 6, 13) . However, only a few studies have been conducted on the growth factors present in of the vasculature and tissues, and it is known that the specialized platelet secretory granules, the α granules, PRP, and on the clinical applications using the drug delivery system (DDS), so that its use has not been widely contain platelet-derived growth factor (PDGF), transforming growth factor-β (TGF-β), insulin-like growth disseminated. In this study, we measured the activity of growth factors present in PRP and determined its poten-factor-I (IGF-I), epidermal growth factor (EGF), endothelial cell growth factor (ECGF), etc. Basic studies have tial clinical effects after developing a new method to prepare PRP containing a higher content of growth factors been conducted on these growth factors (8, 14, 21) , and some growth factors such as PDGF and FGF are avail-through a modification of the centrifugal separation method. In addition, we used fibrin glue as the vehicle for PRP able commercially for use in clinical applications such as skin wound healing. PDGF, TGF-β, IGF-I, etc., are and assessed its use as a DDS, to determine potential clinical utility. also important for bone formation and along with bone morphogenic proteins have attracted attention as factors MATERIALS AND METHODS that promote the proliferation and the differentiation of Experiment 1: Preparation of PRP and Precipitated mesenchymal cells into osteocytes. In considering the Platelet Resuspension (PPR), and Assessment clinical applications of these growth factors, progress of Growth Factor Contents has been reported in the use of recombinant DNA techniques and gene therapy using viral vectors, along with Blood (40 ml) (using 6 ml of acid citrate dextrose: Terumo, Japan) was freshly obtained from 10 healthy studies on the clinical applications of growth factors naturally present in platelets. Particularly in the field of adults (7 men, 3 women), aged 24 to 48 years (mean 32 years old). The whole blood obtained was separated by dentistry, there has been a clinical initiative to test the 510 YAZAWA ET AL. centrifugation at 80 × g for 15 min, and the cellular frac-weight were used. For the collection of fresh blood, the animals were anesthetized by general anesthesia with an tion was removed to yield the plasma fraction (PRP). After removing 1 ml as a PRP sample, the remaining intramuscular injection of ketamine (35 mg/kg; Ketalar, Sankyo Co., Ltd., Japan) and local anesthesia with 2% PRP was further centrifuged at 1000 × g for 7 min, and the precipitated platelet at the bottom of the centrifuge Xylocaine local injection (Fujisawa Pharmaceutical Co., Ltd., Japan). After shaving the fur from the chest area, tube was resuspended in 1 ml of its supernatant [platelet poor plasma (PPP)] to yield PPR (Fig. 1) . The platelet the skin was disinfected with alcohol and 30 ml of fresh blood (containing 4.5 ml acid citrate dextrose) was ob-count and PDGF and TGF-β1 concentrations were measured in the whole blood, PRP, and PPR. The samples tained by intracardiac puncture using a 23-gauge needle. The PRP was then prepared using the protocol described were stored in Eppendorf tubes at −78°C. Before an enzyme-linked immunosorbent assay (ELISA) to analyze in Experiment 1, and was then further centrifuged to prepare the precipitated platelet. This was then resus-growth factor concentrations, the samples were thawed at room temperature. (The measurements were all per-pended in 0.5 ml of fibrin glue (Beriplast; Aventis, Japan) to prepare five sheets of fibrin glue of 8 mm diame-formed by SRL in Japan.) The two-tailed Wilcoxon t-test was used to statistically assess the significance of differ-ter and 2 mm thickness and containing the PPR. The same rabbits from which the blood was taken were anes-ences between groups. Probabilities of less than 0.01 were accepted as significant.
thetized, and the pinna was shaved and sterilized with Isodine solution. Pockets 1 cm in diameter were created, Experiment 2: Evaluation of DDS for PPR four on each side (eight total), under the skin but above the cartilage in the pinna. The fibrin sheets containing Animal Care. The experimental procedure was authorized and reviewed by Keio University Experimental the PPR were inserted into one pinna, while untreated fibrin sheets were inserted into the other pinna as con-Animal Center Committee. Adult Japan white rabbits (Japan Animals Laboratory, Japan) were used in the trols, after which the skin was closed with 5-0 nylon sutures. The sheets, including the entire layer from the present study. All surgery was performed in an animaloperating suite at the university.
pinna, were sampled prior to insertion and at days 1, 3, 5, and 7 after insertion, and frozen sections were pre-Six male Japanese white rabbits of about 3 kg body 
Blood was from 10 healthy adults with a mean age of 32 years (4.95 SD). Values are mean ± SD with percentage in parentheses. pared in the O.C.T. Compound (Tissue-Tek, Japan) by jugated streptavidin-biotin complex (Vector Laboratories, Inc.) was placed on the sections for 30 min, sectioning with a cryostat (CM1900; Leica, Germany). The frozen sections were dried at room temperature and washed three times with PBS, followed by a peroxidase reaction using 3,3′-diaminobenzidine as a chromogen. fixed in acetone (Wako Pure Chemical Industries, Ltd., Japan) for 10 min and then dried, after which the sec-RESULTS tions were stained by the hematoxylin and eosin (H&E) stain and immunostained using the anti-PDGF antibody Experiment 1 (anti-PDGF goat polyclonal IgG; Upstate Biotechnol-Platelet Count. The platelets in PRP were concenogy, USA) to determine the qualitative presence of PDGF trated to a mean of 2.4 times that found in whole blood in the fibrin glue in its evaluation as a DDS.
(p < 0.01) and the platelets in PPR were concentrated to Histological and Immunohistochemical Evaluations. a mean of 3.9 times that found in whole blood ( Table 1 , H&E staining and immunostaining of PDGF antibody Fig. 2 ). were performed. Antibodies for PDGF diluted in PBS PDGF. PDGF in PRP was concentrated to a mean of 1:100 were added to the sections overnight at 4°C and 7.2 times that found in whole blood (p < 0.01) and washed three times with PBS. [Only a negative control PDGF in PPR was concentrated to a mean of 42.6 times section was reacted with normal goat serum (Dako) dithat found in whole blood (p < 0.01) ( Table 1 , Fig. 2 ). luted in PBS 1:100 for 15 min and was washed three times in PBS.] The secondary antibody solution (biotin-TGF-β1. The TGF-β1 in PRP was concentrated to a mean of 6.5 times that found in whole blood (p < 0.01) and ylated rabbit anti-goat IgG; Vector Laboratories, Inc., USA) was placed on the sections for 30 min and washed TGF-β1 in PPR was concentrated to a mean of 18.3 times that found in whole blood (p < 0.01) ( Table 1 , Fig. 2 ). three times with PBS. Then horseradish peroxidase-con- Figure 2 . Assessment of growth factor contents. The platelets in PRP were concentrated to a mean of 2.4 times that found in whole blood and the platelets in PPR were concentrated to a mean of 3.9 times that found in whole blood. PDGF in PRP was concentrated to a mean of 7.2 times that found in whole blood and PDGF in PPR was concentrated to a mean of 42.6 times that found in whole blood. The TGF-β1 in PRP was concentrated to a mean of 6.5 times that found in whole blood and TGF-β1 in PPR was concentrated to a mean of 18.3 times that found in whole blood. *p < 0.01. 
Experiment 2: Histological Examination
Five Days After Insertion. H&E stain showed essentially no change in the shape of the sheet, although the (H&E Staining) and Immunohistochemical Examination (Anti-PDGF Antibody) thickness had decreased by about one half. Anti-PDGF antibody immunostaining showed scattered staining in a Prior to Insertion. H&E stain showed a dense fibrin granular pattern within the fibrin mesh, as indicated in mesh in the internal structure of the fibrin glue sheets. a magnified view of the sheet (Figs. 6 and 8 ). Anti-PDGF antibody immunostaining showed staining in a granular pattern in the sheet throughout the fibrin Seven Days After Insertion. H&E stain showed a loss mesh, indicating the qualitative presence of PDGF in the of the shape of the sheet and a coarser fibrin mesh. Antifibrin glue (Fig. 3) .
PDGF antibody immunostaining showed slight staining within the sheet, as indicated in the magnified view (Figs. One Day After Insertion. H&E stain showed no changes 7 and 8). in the size or the shape of the sheets, while inflammatory cells surrounded the periphery. Anti-PDGF antibody im-DISCUSSION munostaining showed that as seen prior to insertion; there Prior Findings Concerning Clinical Applications was staining in a granular pattern in the sheet throughout of PRP the fibrin mesh, indicating the qualitative presence of PDGF in the fibrin glue ( Figs. 4 and 8) .
Various growth factors are being developed for wound treatment and promotion of bone formation. However, Three Days After Insertion. H&E stain showed essentially no change in the shape of the sheet, although these cytokines have limited effects and must be used individually. In addition, their adverse effects must be the thickness had decreased overall. Anti-PDGF antibody immunostaining showed scattered staining in a characterized, so clinical use requires caution. In contrast, PRP prepared from autologous blood requires no granular pattern within the fibrin mesh, as indicated in a magnified view of the sheet (Figs. 5 and 8) .
special considerations concerning antibody formation or infection risk, and contains large amounts of growth fac-contained in a layer immediately above the buffy coat, and harvesting and recentrifugation of this layer yielded tors, so they have gained attention as being useful in wound healing and bone formation by regulating and PRP. The platelet concentration in PRP prepared by conventional centrifugal gradient methods was 2.4 times inhibiting the various growth factors. Saltz et al. (23), in a clinical study, reported that platelets through PDGF that found in whole blood, and we studied whether or not centrifugation separation at higher speeds can yield and TGF-β promoted wound healing. There have been many recent reports on their use in bone grafting in im-higher growth factor concentrations. The use of a higher centrifugal gradient yielded more concentrated PRP, but plants in the field of oral and maxillofacial surgery. Marx et al. (13) used PRP in a clinical application of the platelets became precipitated, so that the platelets aggregated and degranulated, possibly leading to the re-bone grafting for submaxillary defects after tumor resection, and reported significant rates for the bone graft sur-lease and the loss of growth factors. However, in reality, a PDGF concentration of 42.6 times that found in whole vival and bone formation. Their study reported that platelets at a concentration of 338% of the peripheral blood could be achieved, and higher concentrations were achieved for all growth factors measured. Further stud-blood can be obtained by concentration using a gradient centrifugation method, but did not address the concen-ies are needed to determine whether or not the concentrations can be increased even further, for example, by trations of the specific growth factors present.
adding PGE 1 or PGI 2 during the storage of platelets to The Preparation Method of PRP inhibit platelet degranulation (25,26). We found that higher concentrations of growth fac-Centrifugal separation of whole blood yields three fractions, which in the order of increasing density are tors could be achieved by resuspending the precipitated platelet to give PRP. This may be used potentially in plasma fraction, buffy coat fraction containing mostly white cells, and red cell fraction. The platelets were largely several different ways. 1) It is possible to obtain PRP containing higher concentrations of growth factors as rophage activation, and also enhances the activity of other growth factors (18). It is thought that, normally, 1 needed from autologous blood (there is no wasting of the growth factors collected). 2) The use of an appro-million platelets contain 0.06 ng of PDGF (13). Prior reports (4,5,16) on the involvement of PDGF in wound priate carrier for the precipitated platelet thus prepared may yield a useful DDS system. healing include the study by Pierce et al. (17) , who demonstrated that 0.5 µg of PDGF administered as a single Problems With Concentration administration to a pinna wound in rabbit promoted by Gradient Centrifugation wound healing, and the report by Robson et al. (19, 20) , who administered PDGF at 1-100 µg/ml, once a day for This study demonstrated that it is possible to prepare a precipitated platelet that contains growth factors at 28 days to patients with pressure ulcers, and reported a significantly greater incidence of healing at 100 µg/ml. concentrations higher than the limits that could be achieved by concentrating platelets. This may be due to the re-In the current study the mean PDGF concentration in the PRP was 26 ng/ml, while in the PPR made by resus-lease of growth factors from platelet degranulation, and it will be necessary to study how platelet degranulation pending the precipitated platelet in 1 ml of PPP, the mean PDGF concentration was 152 ng/ml. This concen-during the precipitating process affects the actual clinical applications. How this affects the growth factors tration may not be at the level required when a growth factor is administered alone, and it is not known whether themselves will also need to be assessed. It will also be necessary to study methods to inhibit platelet aggrega-or not this is sufficient to achieve a clinical effect. Even if this concentration is not enough, however, a biological tion to simplify the resuspension process.
PDGF is a growth factor that appears in wounds in the effect may occur when these growth factors associate each other on cell membrane. early phase of clot formation and is synthesized/secreted by platelets, macrophages, and endothelial cells. In wound TGF-β is a central member of the TGF-β superfamily and is synthesized and stored by platelets, macrophages, healing, it promotes mitosis, vessel formation, and mac- and osteoblasts. Among the TGFs, TGF-β1 and TGF-β2 ergy of PDGF and IGF-I was optimal at a ratio of 2:1 by weight, and this combination was superior to PDGF both stimulate the synthesis of collagen matrix in wound healing and the bone regeneration (9), through matura-at 500 ng given alone. These results suggest that multiple growth factors can form a network of growth factors tion and differentiation effects, such as the chemotaxis of osteoblast precursor cells and promotion of mitosis.
to result in a synergistic effect (3,7,10,12). For PRP, which contains various growth factors in addition to Because the target cells are involved in paracrine growth factor and autocrine growth factor mechanisms, these PDGF and TGF-β1 in naturally occurring proportions, we speculate that we may be able to achieve a superior factors are thought to play long-term regulatory roles in wound healing and bone regeneration. As with PDGF, effect at lower concentrations of growth factors compared to the administration of a single growth factor. there have been reports on clinical studies of TGF-β as a single administration. Beck applications its effects must be released slowly, so an have reported on the single administration of 250 ng of appropriate carrier must be developed. Prior studies have TGF-β to linear incisions made through rat dorsal skin.
reported on methods to prepare a gel by adding thrombin The results of this study indicated that in PRP the and calcium chloride to the PRP or using fibrin glue or mean TGF-β content was 128 ng/ml, while the platelet gelatin as carriers, but details of the efficacy of various concentrate made by resuspending the precipitated platecarriers is unknown. There have been some reports on let in 1 ml of PPP contained a mean of 359 ng/ml of the use of fibrin glue as the carrier. Tabata et al. used TGF-β, and it is considered that this may be the minifibrin sheets of 11 mm diameter and 3 mm thickness in mum required to see a clinical effect.
an experiment, and report that in rats with sheet inser-Lynch et al. (11) administered PDGF, IGF-1, EGF, tion in the peritoneum or subcutaneously in the dorsum, and FGF in various combinations to porcine skin wounds about one half of the fibrin sheet remained at 4 days to determine the effect on the healing process. The syn-
